Lumea’s BxBoard ranks third in Utah Innovation Awards MedTech category

Lumea’s BxBoard biopsy transport and preservation container finished third in the 2026 Utah Innovation Awards MedTech Devices & Diagnostics category. The recognition underscores growing attention on tools that improve prostate biopsy quality, reduce lab waste and support more reliable cancer diagnostics.

Why it matters: - The BxBoard aims to improve prostate cancer diagnostics by preserving biopsy tissue integrity from collection through lab processing. - Clinical results tied to the system show smaller waste and better specimen quality, which can affect whether clinicians get enough usable information to guide treatment decisions. - Lumea says the device also reduces formaldehyde exposure and streamlines lab workflow.

What happened: - Lumea said its BxBoard biopsy transportation and preservation container ranked third in the 2026 Utah Innovation Awards MedTech Devices & Diagnostics category. - Utah Business and Nucleus present the annual awards. - The awards honor technological advancements across Utah’s healthcare landscape. - Lumea CEO James Thackeray said the recognition validates the company’s effort to solve a decades-old pathology problem.

The details: - The BxBoard replaces standard formaldehyde jars used for prostate biopsies. - Traditional jars can lead to tissue breakage, curling and compromised specimen integrity. - The BxBoard lets up to six delicate prostate biopsies sit flat on a formalin-soaked sponge within individual lanes. - The design preserves tissue orientation from the moment of collection. - The system is already deployed across more than 130 U.S. clinics. - Clinical studies show a 35% reduction in core fragmentation. - Clinical studies show a 28% increase in measurable core length. - Clinical studies show a 2.1x reduction in test cancellations tied to insufficient quantity or RNA degradation. - Clinical studies show a 92.5% reduction in formaldehyde use per case. - Clinical studies show an 83% reduction in collection containers, blocks and slides required for diagnosis.

Between the lines: - The award points to broader demand for devices that make pathology workflows more efficient without sacrificing specimen quality. - The reduction in formaldehyde use also matters for lab safety, since the chemical is a known carcinogen. - Lumea is positioning tissue-handling technology as part of a larger digital pathology platform, not just a standalone product.

What’s next: - Lumea is likely to continue expanding the BxBoard’s clinic footprint as adoption grows. - The company is also using the award recognition to reinforce its position in digital pathology and cancer diagnostics. - More information about the Utah Business Innovation Awards is available through Utah Business.

The bottom line: - Lumea’s award finish gives third-party validation to a biopsy transport system built to improve prostate tissue preservation, reduce waste and support better diagnostic decisions.